VEGFA and non-small cell lung carcinoma: While our study cohort did not include patients treated with both chemoimmunotherapy and VEGF inhibitors, post-hoc analyses from the IMpower-150 trial involving NSCLC patients with liver metastases have indicated that those who received a combination of carboplatin, paclitaxel, atezolizumab, and bevacizumab experienced improved outcomes compared to those who received only bevacizumab and chemotherapy [32].